From dorzolamide 2%/timolol

Efficacy and tolerability of the fixed combination of

brinzolamide 1% and timolol 0.5% in daily practice

Lanzl I., Raber T

Clinical Ophthalmology 2011:5 1–8

Presented By: Reham Fathy

Glaucoma Product Manager

1 | Subject | Date | Business Use Only

Purpose

to document the efficacy and tolerability of the

new fixed combination brinzolamide 1%/timolol
0.5% as used in daily practice throughout
Germany

2 | Subject | Date | Business Use Only

Patients and methods

POPULATION 14,025 patients from 1161 centers were

analyzed in the study (n = 14,021 evaluable
patients)

METHODS Open-label, multicenter, observational study that

evaluated the transition from prior medication to
brinzolamide /timolol FC for the reduction of
intraocular pressure (IOP)

VISITS Ophthalmologists measured IOP at baseline and

4–6 weeks after transition and assessed their
satisfaction with brinzolamide/timolol FC

3 | Subject | Date | Business Use Only

Results

CHANGE IN MEAN IOP VS PREVIOUS THERAPIES

Change in mean IOP from baseline to 4–6 weeks after transition to

brinzolamide/timolol in patient subgroups with various previous therapies

4 | Subject | Date | Business Use Only

Results

CHANGE IN MEAN IOP VS PREVIOUS THERAPIES

Change in mean intraocular pressure from baseline to 4–6 weeks after transition to
brinzolamide/timolol + a prostaglandin analog in patient subgroups with various previous
therapies.

5 | Subject | Date | Business Use Only

Results

SATISFACTION FOR PATIENTS & INVESTIGATORS

100%
90%
80%
70%
Excellent
60% 87,5% 88,8% Very good
50%
Good
40%
Satisfactory
30%
Not Satisfactory
20%
10%
0%
Patients Investigators

Patient- and investigator-assessed satisfaction with

brinzolamide/timolol after 4–6 weeks of therapy.
6 | Subject | Date | Business Use Only
Results

TOLERABILITY BRINZOLAMIDE/TIMOLOL VS DORZOLAMIDE/TIMOLOL

100% Very good
90% Good
29,2%
80% Moderate
70% Not Satisfactory
60%
88,9%
50%
40%
30%
20%
10%
0%
Dorzolamide/Timolol Brinzolamide/Timolol

Patient-reported tolerability of torzolamide/timolol vs brinzolamide/timolol (n = 2729).

7 | Subject | Date | Business Use Only
Results

REASONS FOR TRANSITION FROM DORZOLAMIDE/TIMOLOL TO BRINZOLAMIDE/TIMOLOL

60%

50%

40%

30%

20%

10%

0%
Intolerance Cost Insuff IOP Compliance Progressive Vascular
to prev ther reduction Lowering vs Disease Aspects
prev ther

n = 2937
8 | Subject | Date | Business Use Only
 Results

TRANSITION FROM DORZOLAMIDE/TIMOLOL TO BRINZOLAMIDE/TIMOLOL

- 2 mmHg
mm Hg

IOP measurement before and after the transition

from dorzolamide/timolol to brinzolamide/timolol
9 | Subject | Date | Business Use Only
Conclusions

The FC brinzolamide/timolol produced

better IOP control than all previous
therapies analyzed and demonstrated
favorable tolerability and a high satisfaction
rating, resulting in a strong patient
preference for brinzolamide/ timolol over
previous therapies

10 | Subject | Date | Business Use Only

 a Novartis company

11 | Subject | Date | Business Use Only